Cardiovascular disorders (CVD), including coronary artery disease (CAD) and congenital hear diseases (CHD) are the leading causes of death in the United States. Despite strong contribution of genetic factors to CVD, very little is known about the underlying genetic causes of these diseases. We have embarked on high throughput sequencing and high throughput in vivo characterization of genes underlying CVD in outlier kindreds and in offsprings of consanguineous unions. Using whole-exome sequencing (WES) and state of the art analytic approaches, from linkage to gene set enrichment analysis, we have identified independent mutations that underlie CAD, metabolic syndrome and diverse CHD. Our success in identification of disease genes is in part due to access to unique disease populations across the world and the support of Yale Center for Mendelian Genomics. While we have devised inventive approaches for novel gene discovery, the distinctive feature of our laboratory is in pursuing the characterization of disease genes in vivo and its success in identifying novel disease pathways and targets for drug development. We have established high throughput techniques in the lab for functional characterization of identified human mutations in vitro and in vivo by employing novel gene editing techniques. Most recently, we have begun to investigate the epigenetic effects of aging, diet and physical activity on disease pathogenesis in human and animal models. Most notably, we have taken a step further and have initiated collaborative efforts with the industry in order to screen and characterize small molecules that can target identified disease pathways in order to rescue cardiovascular and metabolic traits. Our highly cited published work is an attest for the quality and the promising nature of the results we generate in the lab.
Cardiovascular disorders (CVD) are the leading causes of death in the United States. Very little is known about their causes and how to prevent or properly treat them. We have identified mutations in humans that underlie diverse familial CVD and by making animal models of these disorders plan to study how the disease develops and how it can be treated.
|Goetz, Laura G; Mamillapalli, Ramanaiah; Sahin, Cagdas et al. (2018) Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE-/- Mice. Endocrinology 159:754-762|
|Abou Ziki, M D; Seidelmann, S B; Smith, E et al. (2018) Deleterious protein-altering mutations in the SCN10A voltage-gated sodium channel gene are associated with prolonged QT. Clin Genet 93:741-751|
|Abou Ziki, Maen D; Mani, Arya (2018) The interplay of canonical and noncanonical Wnt signaling in metabolic syndrome. Nutr Res :|
|Goyal, Amit; Keramati, Ali R; Czarny, Matthew J et al. (2017) The Genetics of Aortopathies in Clinical Cardiology. Clin Med Insights Cardiol 11:1179546817709787|
|Mani, Arya (2017) Fragmented QRS: A marker of hypertensive heart disease? J Clin Hypertens (Greenwich) 19:866-867|
|Abou Ziki, Maen D; Mani, Arya (2017) Wnt signaling, a novel pathway regulating blood pressure? State of the art review. Atherosclerosis 262:171-178|
|Mani, Arya (2017) Local Ancestry Association, Admixture Mapping, and Ongoing Challenges. Circ Cardiovasc Genet 10:|
|Hwangbo, Cheol; Wu, Jingxia; Papangeli, Irinna et al. (2017) Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects. Sci Transl Med 9:|
|Mani, Arya (2017) Pathogenicity of De Novo Rare Variants: Challenges and Opportunities. Circ Cardiovasc Genet 10:|
|Masoudkabir, Farzad; Sarrafzadegan, Nizal; Gotay, Carolyn et al. (2017) Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 263:343-351|
Showing the most recent 10 out of 11 publications